Diseases of Abnormal Sensitivity to Cold in Children on Psychostimulant Drugs

被引:9
作者
Coulombe, Jerome [1 ]
Powell, Julie
Hatami, Afshin
McCuaig, Catherine
Renet, Sophie
Marcoux, Danielle
机构
[1] CHU Ste Justine, Pediat Dermatol Div, Montreal, PQ H3T 1C5, Canada
关键词
DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PERIPHERAL VASCULOPATHY; LIFE-SPAN;
D O I
10.2310/7750.2014.14052
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Oral psychostimulant (PS) drugs, the pharmacologic treatment of choice for attention-deficit/hyperactivity disorder (ADHD), have been associated with diseases of abnormal sensitivity to cold (DASC) such as Raynaud phenomenon and acrocyanosis. Objectives: In a cohort of pediatric patients with DASC, we sought to identify prevalence and clinical features of patients on PS drugs. Methods: A 6-year retrospective chart review (2005-2011) of Ste-Justine University Hospital Center DASC patients with and without exposure to PS drugs was performed. Clinical data were analyzed with descriptive statistical methods. Results: Of 43 patients with DASC, 11 (25%) were exposed to PS drugs. In this group males were overrepresented, there was no evidence of collagen vascular diseases, serologic findings were not significant and the mean duration of PS intake was of 2.5 years. DASC age of onset was similar in both exposed and nonexposed patients. The incidence of more than one DASC type was greater in teenager patients with a positive family history of autoimmune and/or collagen vascular diseases. Limitations: This study is limited by its small population size, short follow-up period and its retrospective nature. Conclusion: Physicians should be aware of PS drugs as possible triggers for DASC.
引用
收藏
页码:121 / 124
页数:4
相关论文
共 13 条
  • [1] Blue toes after stimulant therapy for pediatric attention deficit hyperactivity disorder
    Al Aboud, Ahmad
    Abrams, Melissa
    Mancini, Anthony J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (06) : 1218 - 1219
  • [2] Biederman J, 1998, J CLIN PSYCHIAT, V59, P4
  • [3] Burns T., 2013, Rook's Textbook of Dermatology
  • [4] Treatment of attention-deficit-hyperactivity disorder
    Elia, J
    Ambrosini, PJ
    Rapoport, JL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) : 780 - 788
  • [5] Association between treatment with central nervous system stimulants and Raynaud's syndrome in children
    Goldman, William
    Seltzer, Ryan
    Reuman, Peter
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (02): : 563 - 566
  • [6] Attention deficit hyperactivity disorder across the lifespan: The child, adolescent, and adult
    Greydanus, Donald E.
    Pratt, Helen D.
    Patel, Dilip R.
    [J]. DM DISEASE-A-MONTH, 2007, 53 (02): : 70 - 131
  • [7] Homer CJ, 2000, PEDIATRICS, V105, P1158
  • [8] Clinical utility of antinuclear antibody tests in children
    McGhee J.L.
    Kickingbird L.M.
    Jarvis J.N.
    [J]. BMC Pediatrics, 4 (1)
  • [9] Attention deficit-hyperactivity disorder
    Rappley, MD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (02) : 165 - 173
  • [10] CEREBRAL MICROVASCULAR INJURY IN EXPERIMENTAL DRUG-ABUSE
    RUMBAUGH, CL
    FANG, HCH
    HIGGINS, RE
    BERGERON, RT
    SEGALL, HD
    TEAL, JS
    [J]. INVESTIGATIVE RADIOLOGY, 1976, 11 (04) : 282 - 294